Journal
ONCOTARGET
Volume 7, Issue 3, Pages 2754-2764Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.6666
Keywords
bladder cancer; epigenetics; methylation; biomarkers; qMSP
Categories
Funding
- National Natural Science Foundation [81301740]
- Shenzhen Basic Research Project [JCYJ20130401114928183]
- Shenzhen Knowledge Innovation Project [JCYJ201304011 14715714, JSGG20130411091246833, CXZZ20130 516153248144]
Ask authors/readers for more resources
To develop a routine and effectual procedure of detecting bladder cancer (BlCa), an optimized combination of epigenetic biomarkers that work synergistically with high sensitivity and specificity is necessary. In this study, methylation levels of seven biomarkers (EOMES, GDF15, NID2, PCDH17, POU4F2, TCF21, and ZNF154) in 148 individuals-which including 58 urothelial cell carcinoma (UCC) patients, 20 infected urinary calculi (IUC) patients, 20 kidney cancer (KC) patients, 20 prostate cancer (PC) patients, and 30 healthy volunteers (HV)-were quantified by qMSP using the urine sediment DNA. Receiver operating characteristic (ROC) curves were generated for each biomarker. The combining predictors of possible combinations were calculated through logistic regression model. Subsequently, ROC curves of the three best performing combinations were constructed. Then, we validated the three best performing combinations and POU4F2 in another 72 UCC, 21 IUC, 26 KC and 22 PC, and 23 HV urine samples. The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available